Incyte Tumbles On More Jakafi Trial Terminations

Incyte Corporation is discontinuing all ongoing trials for its Janus kinase inhibitor, Jakafi (ruxolitinib), in solid tumors following poor results in a Phase III study in metastatic pancreatic cancer and in a recently suspended Phase II colorectal cancer trial.